Back to search results

Peripheral Nerve Stimulation for Chemotherapy-Induced Pain

This study is looking at whether peripheral nerve stimulation (PNS) can help reduce pain caused by chemotherapy (chemo-induced peripheral neuropathy or CIPN). CIPN is nerve damage that can cause pain, numbness, and tingling. Researchers want to see if PNS, which involves placing small wires (leads) near nerves to deliver electrical pulses, can improve your pain. They will also look at how PNS affects your daily activities and overall well-being. You might be able to join if you are between 18 and 85 years old, have chronic CIPN in your legs from certain chemotherapy drugs, and experience pain levels of 4 or higher on a 0-10 scale. The study aims to enroll 10 participants.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It is a single-center feasibility study with a planned enrollment of 10 participants.
What's involved
The leads for peripheral nerve stimulation are inserted through a needle, potentially with local anesthetic. Safety and side effects will be monitored for about one year.
Compensation
Not stated in the trial record.
Follow-up
Safety and adverse events will be measured through study completion, which is an average of one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06162403

Exploring the Benefit of Peripheral Nerve Stimulation in Treating Pain From Chemo-induced Peripheral Neuropathy: A Longitudinal Single Center Feasibility Study

Recruiting
NAAges 18–85InterventionalSupportive care
M.D. Anderson Cancer Center
~10 participants
Updated 2026-08-10 on ClinicalTrials.gov
What's tested:Peripheral Nerve Stimulation

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and adverse events (AEs)
Measured over Through study completion; an average of 1 year.

Conditions

Peripheral Nerve Stimulation
Chemotherapy-induced Peripheral Neuropathy

Explore related trials

Chemotherapy-Induced Peripheral Neuropathy

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Saba Javed, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Saba Javed, MD
[email protected]
(713) 792-9530
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants diagnosed with chronic (≥90 days duration) CIPN (due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds or ionizing irradiation) of the lower extremity, seen at Pain Management Center at MD Anderson Cancer Center
Participants reports baseline pain ≥ 4 (0-10 scale, NRS)
Participants between ages 18-85 years old
Participants who have completed chemotherapy within the previous year at the time of enrollment

Exclusion

Participants with cognitive dysfunction
Participants with recent history (\<6 months) of drug or alcohol abuse
Participants with open skin lesion or undergoing antibiotic therapy for local for systemic infection
Participants with allergies to local anesthesia, steroids, or adhesives
Participants with conditions that conflict with the SPRINT PNS System Indications for Use, including Contraindications and Warnings.

What this trial measures

  • Safety and adverse events (AEs)Through study completion; an average of 1 year.

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0